Sandbox/intraabdominal: Difference between revisions
< Sandbox
No edit summary |
|||
Line 241: | Line 241: | ||
{| | {| | ||
| valign=top | | | valign=top | | ||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: | <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 40px; line-height: 40px; width: 225px; background: #A1BCDD; text-align: center;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
'''Multidrug resistant gram-negative bacilli''' | '''Multidrug resistant gram-negative bacilli''' |
Revision as of 16:49, 12 June 2014
Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection
Pediatric patients ▸ Single agent ▸ Combination Adults, mild-to-moderate severity ▸ Single agent ▸ Combination Adults, high risk or severity ▸ Single agent ▸ Combination |
|
Empiric Antimicrobial Therapy for Health Care-Associated Complicated Intra-abdominal Infection
Multidrug resistant gram-negative bacilli ▸ Regimen ESBL-Enterobacteriaceae ▸ Regimen P. aeruginosa >20% resistant to ceftazidime ▸ Regimen ▸ Regimen |
|